All Updates

All Updates

icon
Filter
Partnerships
BenevolentAI and AstraZeneca extends collaboration with novel target for systemic lupus erythematosus
AI Drug Discovery
Jun 25, 2024
This week:
Partnerships
Sheeva.AI and P97 Networks partner for in-car payment solutions at fuel stations
Auto Tech
Today
Product updates
Food Cycle Science launches 'Food Cycler Eco 3,' a household food waste processing bin
Food Waste
Yesterday
Partnerships
Von Holzhausen and Herman Miller partner to launch plant-based leather Eames Chair
Bio-based Materials
Yesterday
Partnerships
Volvo Cars partners with Beijing Shougang and Zhejiang Yiyun for automotive steel recycling
Waste Recovery & Management Tech
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Carbon Capture, Utilization & Storage (CCUS)
Yesterday
Funding
LanzaJet receives strategic investment from Airbus
Alternative Energy
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
Pet Care Tech
Yesterday
Partnerships
Odie Pet Insurance partners with Insuritas to offer pet coverage through financial institutions
InsurTech: Personal Lines
Yesterday
M&A
Applied Systems acquires Planck for undisclosed sum to expand AI capabilities
InsurTech: Infrastructure
Yesterday
Product updates
Monzo launches pension consolidation product
Neobanks
Yesterday
AI Drug Discovery

AI Drug Discovery

Jun 25, 2024

BenevolentAI and AstraZeneca extends collaboration with novel target for systemic lupus erythematosus

Partnerships

  • AI-powered biotechnology company BenevolentAI, in collaboration with AstraZeneca, has announced that a novel target for systemic lupus erythematosus (SLE) has been added to its discovery portfolio.

  • The partnership, initiated in 2019, leverages BenevolentAI's AI drug discovery platform to develop novel therapeutic targets tested and validated by AstraZeneca. The collaborative research was initiated focusing on idiopathic pulmonary fibrosis and chronic kidney disease and was extended in 2022 , expanding the study to include heart failure and SLE.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.